MA38272A1 - Peptides en tant qu'agonistes de l'oxytocine - Google Patents
Peptides en tant qu'agonistes de l'oxytocineInfo
- Publication number
- MA38272A1 MA38272A1 MA38272A MA38272A MA38272A1 MA 38272 A1 MA38272 A1 MA 38272A1 MA 38272 A MA38272 A MA 38272A MA 38272 A MA38272 A MA 38272A MA 38272 A1 MA38272 A1 MA 38272A1
- Authority
- MA
- Morocco
- Prior art keywords
- lower alkyl
- group
- alkyl group
- hydroxy
- hydrogen atom
- Prior art date
Links
- 102400000050 Oxytocin Human genes 0.000 title 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title 1
- 101800000989 Oxytocin Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
- 229960001723 oxytocin Drugs 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 230000036506 anxiety Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- -1 -ch2-cycloalkyl Chemical group 0.000 abstract 1
- 208000000044 Amnesia Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 102000004279 Oxytocin receptors Human genes 0.000 abstract 1
- 108090000876 Oxytocin receptors Proteins 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 208000029650 alcohol withdrawal Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 230000006984 memory degeneration Effects 0.000 abstract 1
- 208000023060 memory loss Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des composés de formule (i) dans laquelle r1 est un groupe hydroxy ou amino; r2 est un groupe sec-butyle ou isobutyle; r3 est un groupe alkyle inférieur, alkyle inférieur substitué par un groupe hydroxy, -(ch2)2c(o)-nh2, -(ch2)3-nh2 ou - ch2-groupe hétérocyclique aromatique à cinq chaînons; r4 représente un atome d'hydrogène ou un groupe alkyle inférieur; r5 représente l'hydrogène ou un groupe alkyle inférieur; ou r4 et r5 peuvent former conjointement avec l'atome n et c auquel ils sont attachés un cycle pyrrolidine éventuellement substitué par un groupe hydroxy ou un atome d'halogène, un cycle pipéridine ou un cycle azétidine; r6 représente un atome d'hydrogène, un groupe alkyle inférieur, un groupe alkyle inférieur substitué par un groupe hydroxy, -(ch2)2c(o)oh, -(ch2)2c(o)nh2, un groupe benzyle éventuellement substitué par un groupe amino ou hydroxy, -ch2-groupe hétérocyclique aromatique à cinq chaînons, indolyle, -ch2-cycloalkyle, cycloalkyle, -(ch2)2-s-alkyle inférieur ou est -(ch2)1-4-nh2; r6' représente un atome d'hydrogène ou un groupe alkyle inférieur; ou r6 et r6 forment ensemble un groupe cycloalkyle; x est -c(o)-chr-nr'-c(o)-; r/r' sont indépendamment l'un de l'autre un atome d'hydrogène ou un groupe alkyle inférieur; m vaut 2; o vaut 0 ou 1; ou un sel d'addition d'acide pharmaceutiquement acceptable, un mélange racémique ou son énantiomère correspondant et/ou ses isomères optiques. On a trouvé que les présents composés sont des agonistes de récepteur de l'oxytocine pour le traitement de l'autisme, du stress, y compris d'un trouble de stress post-traumatique, de l'anxiété, y compris des troubles d'anxiété et d'une dépression, de la schizophrénie, de troubles psychiatriques et de perte de mémoire, du sevrage alcoolique, de la toxicomanie et pour le traitement du syndrome de prader-willi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12199012 | 2012-12-21 | ||
| PCT/EP2013/076783 WO2014095773A1 (fr) | 2012-12-21 | 2013-12-17 | Peptides en tant qu'agonistes de l'oxytocine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38272A1 true MA38272A1 (fr) | 2017-07-31 |
Family
ID=47471593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38272A MA38272A1 (fr) | 2012-12-21 | 2013-12-17 | Peptides en tant qu'agonistes de l'oxytocine |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9868766B2 (fr) |
| EP (1) | EP2935312B1 (fr) |
| JP (1) | JP6067878B2 (fr) |
| KR (1) | KR101819804B1 (fr) |
| CN (1) | CN104870466B (fr) |
| AR (1) | AR094225A1 (fr) |
| AU (1) | AU2013363768B2 (fr) |
| BR (1) | BR112015014010A2 (fr) |
| CA (1) | CA2895150C (fr) |
| CL (1) | CL2015001724A1 (fr) |
| CR (1) | CR20150271A (fr) |
| DK (1) | DK2935312T3 (fr) |
| EA (1) | EA026687B1 (fr) |
| ES (1) | ES2690317T3 (fr) |
| HR (1) | HRP20181569T1 (fr) |
| HU (1) | HUE039848T2 (fr) |
| IL (1) | IL239519A (fr) |
| LT (1) | LT2935312T (fr) |
| MA (1) | MA38272A1 (fr) |
| MX (1) | MX358684B (fr) |
| MY (1) | MY176398A (fr) |
| NZ (1) | NZ708175A (fr) |
| PE (1) | PE20151446A1 (fr) |
| PH (1) | PH12015501145B1 (fr) |
| PL (1) | PL2935312T3 (fr) |
| PT (1) | PT2935312T (fr) |
| RS (1) | RS57690B1 (fr) |
| SG (1) | SG11201504883PA (fr) |
| SI (1) | SI2935312T1 (fr) |
| TW (1) | TWI558726B (fr) |
| UA (1) | UA119034C2 (fr) |
| WO (1) | WO2014095773A1 (fr) |
| ZA (1) | ZA201504186B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013139861A1 (fr) | 2012-03-20 | 2013-09-26 | Luc Montagnier | Procédés et compositions pharmaceutiques pour le traitement de troubles du syndrome de l'autisme |
| CN110684067A (zh) | 2012-12-21 | 2020-01-14 | 艾丽奥斯生物制药有限公司 | 取代的核苷和核苷酸 |
| EA026687B1 (ru) | 2012-12-21 | 2017-05-31 | Ф. Хоффманн-Ля Рош Аг | Пептиды в качестве агонистов окситоцина |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| KR102116107B1 (ko) | 2013-12-30 | 2020-05-28 | 삼성디스플레이 주식회사 | 표시 장치 |
| US9988421B2 (en) | 2014-01-10 | 2018-06-05 | Cornell University | Dipeptides as inhibitors of human immunoproteasomes |
| EA030091B1 (ru) | 2014-06-03 | 2018-06-29 | Ф. Хоффманн-Ля Рош Аг | Пептиды, выполняющие роль агонистов окситоцина |
| AP2016009605A0 (en) | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| SI3177635T1 (sl) * | 2014-08-07 | 2019-01-31 | F. Hoffmann-La Roche Ag | Postopki za pripravo analogov oksitocina |
| EP3193904B1 (fr) * | 2014-08-18 | 2025-10-01 | Cornell University | Dipeptidomimetiques en tant qu'inhibiteurs des immunoproteasomes humains |
| CA2957224A1 (fr) * | 2014-09-19 | 2016-03-24 | Ferring B.V. | Procede de traitement de syndrome prader-willi |
| EP3362754B1 (fr) | 2015-10-15 | 2021-12-22 | Cornell University | Inhibiteurs des protéasomes et leurs utilisations |
| EP3694605A4 (fr) | 2017-10-11 | 2021-10-27 | Cornell University | Inhibiteurs peptidomimétiques du protéasome |
| CN112839632A (zh) | 2018-09-20 | 2021-05-25 | 莱沃疗法公司 | 稳定的鼻内卡贝缩宫素制剂 |
| AU2019345313A1 (en) | 2018-09-20 | 2021-03-18 | Levo Therapeutics, Inc. | Carbetocin drug product and process for preparing same |
| WO2021126990A1 (fr) * | 2019-12-16 | 2021-06-24 | The Scripps Research Institute | Dérivés d'ocytocine ayant des propriétés améliorées |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140716T1 (hr) | 2008-03-31 | 2014-08-29 | Ferring B.V. | Analozi oksitocina |
| TWI463990B (zh) | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| US9119805B2 (en) * | 2009-10-01 | 2015-09-01 | The University Of Sydney | Therapy and prevention of problem drinking |
| EA026687B1 (ru) | 2012-12-21 | 2017-05-31 | Ф. Хоффманн-Ля Рош Аг | Пептиды в качестве агонистов окситоцина |
-
2013
- 2013-12-17 EA EA201591078A patent/EA026687B1/ru not_active IP Right Cessation
- 2013-12-17 MX MX2015007365A patent/MX358684B/es active IP Right Grant
- 2013-12-17 KR KR1020157016376A patent/KR101819804B1/ko not_active Expired - Fee Related
- 2013-12-17 WO PCT/EP2013/076783 patent/WO2014095773A1/fr not_active Ceased
- 2013-12-17 NZ NZ708175A patent/NZ708175A/en not_active IP Right Cessation
- 2013-12-17 HU HUE13814079A patent/HUE039848T2/hu unknown
- 2013-12-17 SI SI201331190T patent/SI2935312T1/sl unknown
- 2013-12-17 CA CA2895150A patent/CA2895150C/fr not_active Expired - Fee Related
- 2013-12-17 PL PL13814079T patent/PL2935312T3/pl unknown
- 2013-12-17 CN CN201380066617.7A patent/CN104870466B/zh not_active Expired - Fee Related
- 2013-12-17 LT LTEP13814079.3T patent/LT2935312T/lt unknown
- 2013-12-17 MA MA38272A patent/MA38272A1/fr unknown
- 2013-12-17 HR HRP20181569TT patent/HRP20181569T1/hr unknown
- 2013-12-17 BR BR112015014010A patent/BR112015014010A2/pt not_active IP Right Cessation
- 2013-12-17 UA UAA201506906A patent/UA119034C2/uk unknown
- 2013-12-17 PT PT13814079T patent/PT2935312T/pt unknown
- 2013-12-17 ES ES13814079.3T patent/ES2690317T3/es active Active
- 2013-12-17 MY MYPI2015001585A patent/MY176398A/en unknown
- 2013-12-17 PE PE2015001058A patent/PE20151446A1/es unknown
- 2013-12-17 AU AU2013363768A patent/AU2013363768B2/en not_active Ceased
- 2013-12-17 SG SG11201504883PA patent/SG11201504883PA/en unknown
- 2013-12-17 RS RS20181124A patent/RS57690B1/sr unknown
- 2013-12-17 JP JP2015548420A patent/JP6067878B2/ja not_active Expired - Fee Related
- 2013-12-17 EP EP13814079.3A patent/EP2935312B1/fr not_active Not-in-force
- 2013-12-17 DK DK13814079.3T patent/DK2935312T3/en active
- 2013-12-20 AR ARP130104962A patent/AR094225A1/es unknown
- 2013-12-20 TW TW102147655A patent/TWI558726B/zh not_active IP Right Cessation
-
2015
- 2015-05-21 CR CR20150271A patent/CR20150271A/es unknown
- 2015-05-22 PH PH12015501145A patent/PH12015501145B1/en unknown
- 2015-06-10 ZA ZA2015/04186A patent/ZA201504186B/en unknown
- 2015-06-18 US US14/743,009 patent/US9868766B2/en not_active Expired - Fee Related
- 2015-06-18 IL IL239519A patent/IL239519A/en active IP Right Grant
- 2015-06-18 CL CL2015001724A patent/CL2015001724A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38272A1 (fr) | Peptides en tant qu'agonistes de l'oxytocine | |
| US12024499B2 (en) | Muscarinic agonists | |
| US10406144B2 (en) | SIP modulating agents | |
| MA42442B1 (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
| EA201692558A1 (ru) | Производные индолин-2-она или пирролопиридин-2-она | |
| AU2014212465A1 (en) | S1P modulating agents | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| PH12016502251A1 (en) | Peptides as oxytocin agonists | |
| MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
| MX2015008830A (es) | Agonistas del receptor de oxitocina para el tratamiento de enfermedades del sistema nervioso central. | |
| PH12016502232A1 (en) | Peptides as oxytocin agonists | |
| MA38011B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5 | |
| US12486228B2 (en) | N-substituted indoles and use as allosteric modulators of cannabinoid receptors | |
| US11931332B2 (en) | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | |
| BG63392B1 (bg) | Производни на 5-нафтален-1-ил-1,3-диоксан, тяхното получаване и използването им като терапевтични средства | |
| MA34251B1 (fr) | Derives amido-tropane |